Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

NCT06255626 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

215

Enrollment

OTHER_GOV

Sponsor class

Conditions

COVID-19

Interventions

DRUG: CD40.RBDv vaccin (SARS-Cov2 Vaccin)

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]
[object Object]